Trial Profile
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Proliferative Lupus Nephritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jan 2024
Price :
$35
*
At a glance
- Drugs Anifrolumab (Primary) ; Glucocorticoids; Mycophenolate mofetil
- Indications Lupus nephritis
- Focus Proof of concept; Therapeutic Use
- Acronyms TULIP-LN; TULIP-LN1
- Sponsors AstraZeneca
- 15 Nov 2023 Results (n=117) assessing untargeted metabolomics profiling on urine samples from the phase 2 trial to identify markers associated with LN disease activity that were modulated by anifrolumab, presented at the ACR Convergence 2023.
- 03 Jun 2023 Results assessing unbiased metabolomic serum profiling to determine novel biomarkers of treatment response and provide insights into the mechanism of action of anifrolumab presented at the 24th Annual Congress of the European League Against Rheumatism
- 14 Nov 2022 Results (from two studies n=131 from NCT02547922 and n=59 from NCT02446912) hypothesizing that Renal Activity Index for Lupus (RAIL) is effective in distinguishing inactive vs active LN and can differentiate LN treatment responders from non-responders in adult patients presented at the ACR Convergence 2022